KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Change in Cash (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Change in Cash for 15 consecutive years, with -$22.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Cash fell 160.87% to -$22.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $60.6 million, a 1158.31% increase, with the full-year FY2025 number at $60.6 million, up 1158.31% from a year prior.
  • Change in Cash was -$22.9 million for Q4 2025 at Supernus Pharmaceuticals, down from $8.1 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $369.1 million in Q1 2023 to a low of -$437.5 million in Q2 2023.
  • A 5-year average of -$7.9 million and a median of -$11.8 million in 2021 define the central range for Change in Cash.
  • Biggest YoY gain for Change in Cash was 520.75% in 2023; the steepest drop was 858.05% in 2023.
  • Supernus Pharmaceuticals' Change in Cash stood at -$11.8 million in 2021, then plummeted by 55.08% to -$18.4 million in 2022, then decreased by 8.49% to -$19.9 million in 2023, then soared by 288.94% to $37.7 million in 2024, then plummeted by 160.87% to -$22.9 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Change in Cash are -$22.9 million (Q4 2025), $8.1 million (Q3 2025), and $28.9 million (Q2 2025).